SGSH gene

MPS IIIA, or Sanfilippo syndrome type A, is primarily characterized by severe neurodegeneration, including progressive cognitive decline, behavioral disturbances (such as hyperactivity, aggression, or sleep disturbances), and loss of speech. Unlike other MPS types where physical features like coarse facial features, joint stiffness, and organomegaly are prominent, MPS IIIA patients often have milder somatic symptoms. The neurological deterioration is the hallmark, typically leading to a loss of ambulation and severe disability within the first decade of life. How is MPS IIIA diagnosed, and why is newborn screening important for this condition?::Diagnosis is confirmed through enzyme analysis showing deficient sulfamidase activity in dried blood spots or leukocytes, followed by genetic testing of the SGSH gene to identify specific mutations. Newborn screening is critical because early detection allows for family counseling and preparation for supportive care. While there is no cure, early identification helps families access specialized multidisciplinary care teams, manage behavioral and medical complications proactively, and participate in emerging clinical trials. What are the current treatment options for managing the symptoms of MPS IIIA?::Currently, there is no disease-modifying therapy that halts the progression of MPS IIIA. Management is supportive and focuses on alleviating symptoms. This includes behavioral interventions for hyperactivity and sleep issues, physical therapy to maintain mobility as long as possible, and speech therapy. Medications may be used to manage specific symptoms like agitation or sleep disturbances. Research into gene therapy and enzyme replacement therapy is ongoing, but these are not yet standard clinical treatments.